News | 07 July 2023
Aster DM Healthcare increases stake in Malabar Institute of Medical Sciences
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Cipla has a robust governance model focused on sustainability
PEEK brings a new quality to dental care for patients
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
OVAPEX is a unique formula developed by the team of scientists and doctors at Green Milk Concepts
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The VITA-FAST tokens have been met with overwhelming interest
Subscribe To Our Newsletter & Stay Updated
